PubRank

Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19

Clinical Trial ID NCT00466531

PubWeight™ 45.17‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00466531

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011 7.49
2 Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol Ther 2010 4.54
3 Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood 2010 3.57
4 The basic principles of chimeric antigen receptor design. Cancer Discov 2013 3.28
5 Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. J Immunother 2009 3.11
6 Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 2014 2.84
7 Gene-engineered T cells for cancer therapy. Nat Rev Cancer 2013 2.07
8 Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol 2013 1.91
9 Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies. Int J Hematol 2013 1.64
10 Adoptive immunotherapy for cancer or viruses. Annu Rev Immunol 2014 1.61
11 Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies. Hum Gene Ther 2012 1.29
12 Adoptive immunotherapy for B-cell malignancies with autologous chimeric antigen receptor modified tumor targeted T cells. Discov Med 2010 0.99
13 Antigen-Specific T-Cell Activation Independently of the MHC: Chimeric Antigen Receptor-Redirected T Cells. Front Immunol 2013 0.98
14 Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies. Cancer Gene Ther 2015 0.97
15 Strategy escalation: an emerging paradigm for safe clinical development of T cell gene therapies. J Transl Med 2010 0.95
16 Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression. Mol Ther 2015 0.91
17 Driving CAR-based T-cell therapy to success. Curr Hematol Malig Rep 2014 0.89
18 A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer. J Transl Med 2015 0.89
19 Cell-based strategies to manage leukemia relapse: efficacy and feasibility of immunotherapy approaches. Leukemia 2014 0.86
20 Clinical development of gene therapy: results and lessons from recent successes. Mol Ther Methods Clin Dev 2016 0.85
21 Adoptive T-cell therapies for refractory/relapsed leukemia and lymphoma: current strategies and recent advances. Ther Adv Hematol 2015 0.82
22 Targeting CD8+ T-cell tolerance for cancer immunotherapy. Immunotherapy 2014 0.81
23 Engineered T cells for the adoptive therapy of B-cell chronic lymphocytic leukaemia. Adv Hematol 2011 0.79
24 Cellular therapies in acute lymphoblastic leukemia. Curr Opin Mol Ther 2009 0.77
25 Using gene therapy to manipulate the immune system in the fight against B-cell leukemias. Expert Opin Biol Ther 2015 0.77
26 Chimeric antigen receptor therapy for chronic lymphocytic leukemia: what are the challenges? Hematol Oncol Clin North Am 2013 0.76
27 Chimeric antigen receptors and bispecific antibodies to retarget T cells in pediatric oncology. Pediatr Blood Cancer 2015 0.75
Next 100